CSPC Pharmaceutical Group Out-Licenses Western Rights For Cancer Drug To Dexcel

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

May 12, 2014 -- CSPC Pharmaceutical Group, headquartered in China's Heibei Province, has partnered with Dexcel Pharma Technologies to co-develop and commercialize a generic oncology drug in the US, Europe and elsewhere. Dexcel is a privately held Israeli generic drug company, with a presence in more than 30 countries. Dexcel will pay CSPC $2 million to defray the pre-clinical and cGMP compliance certification costs. It will also be liable for up to $5 million in milestones, and Dexcel will be responsible for obtaining approvals of the product. More details....

Stock Symbol: (HK: 1093)

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC